<DOC>
	<DOCNO>NCT01185171</DOCNO>
	<brief_summary>The purpose study explore activity ZD1839 add concurrent chemoradiotherapy adjuvant monotherapy patient locally advanced head neck cancer . Activity describe term response rate ( complete response ) .</brief_summary>
	<brief_title>Trial Induction Chemotherapy With Carboplatin Paclitaxel , Followed Concurrent Chemotherapy/Radiation Therapy With ZD1839 ( IRESSA ) , 5-FU , Hydroxyurea , Twice-Daily Radiation , Followed Adjuvant ZD1839 Monotherapy Patients With Locally Advanced Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis squamous cell poorly differentiate carcinoma , lymphoepithelioma nasopharynx . 2 . Age 18 year old . 3 . Patients AJCC ( 6th edition , 2002 ) stage III IV head neck cancer . 4 . Patients AJCC ( 6th edition , 2002 ) stage IV head neck cancer . present cervical lymph node metastasis unknown primary ( i.e. , TxN2 TxN3 ) also eligible . 5 . Prior entry study , resectability alternative treatment option patient determine team compose head neck surgeon , radiation oncologist , medical oncologist . Stage determination , optimal local treatment , time accord protocol determine evaluation . Each patient classify resectable unresectable disease . The unequivocal demonstration distant metastasis ( M1 ) confers ineligibility . 6 . Unidimensionally measurable disease ( base RECIST ) desirable strictly require . Individuals disease free baseline excisional biopsy node dissection consider evaluable response assessment eligible . 7 . No prior radiotherapy . 8 . Prior surgical therapy consist incisional excisional biopsy organsparing procedure debulking airwaycompromising tumor neck dissection patient unknown primary tumor . 9 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ( Karnofsky ≥ 60 % . 10 . Patients must normal organ marrow function define absolute neutrophil count ( ANC ) ≥ 1,500/μl platelet ≥ 100,000/μl total bilirubin within normal institutional limit aspartate aminotransferase ( AST , SGOT ) / alanine aminotransferase ( ALT , SGPT ) ≤ 2.5 × institutional upper limit normal alkaline phosphatase ≤ 2 × upper limit normal creatinine within normal institutional limit 1 . Unequivocal demonstration metastatic disease ( i.e . M1 disease ) . 2 . Known severe hypersensitivity ZD1839 excipients product . 3 . Any coexisting malignancy would increase risk toxicity , interfere interpretation toxicity , associate median survival le 24 month . 4 . Concomitant use phenytoin , carbamazepine , barbiturate , rifampin , phenobarbital , St.John 's Wort . 5 . Treatment investigational drug within 30 day Day 1 trial treatment . 6 . Incomplete heal previous surgery . 7 . Pregnancy breast feeding ( woman childbearing potential ) . Patients advise use effective contraception appropriate . 8 . History allergic reaction attribute compound similar chemical biologic composition paclitaxel , Cremaphor EL , carboplatin , 5 FU , hydroxyurea . 9 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( CHF ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 10 . Patients clinically significant pulmonary dysfunction , cardiomyopathy , history clinically significant CHF exclude . The exclusion patient active coronary artery disease discretion attend physician . 11 . Patients must uncontrolled active infection curable without treatment cancer . 12 . No patient severe baseline neurologic deficit ( &gt; grade II neuropathy ) treat induction chemotherapy . 13 . Any evidence clinically active interstitial lung disease ( patient chronic stable radiographic change asymptomatic need exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Larynx</keyword>
	<keyword>Lip</keyword>
	<keyword>Oral Cavity Pharynx</keyword>
</DOC>